Novo Nordisk spies great hemophilia opportunities with partner Genmab
Pharmaceutical firm Novo Nordisk is expecting to send a new hemophilia drug to the market in 2025. It might end up being one of the best, according to Novo exec Martin Holst Lange.
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen
Novo Nordisk’s lucrative biopharma arm has stopped hemorrhaging, but growth is still a way away following years of this being the status quo. The hemophilia treatment Mim8 could speed up this process.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biopharma sales slightly lower than expected at Novo Nordisk
For subscribers
